Sensorion published its full-year 2025 results and corporate update, alongside the release of its annual report. The company reported FY 2025 operating income of EUR 5.81 million and a net loss of EUR 29.43 million. Cash and cash equivalents were EUR 47.46 million at year-end, and Sensorion said it received net proceeds of around EUR 56 million from a EUR 60 million private placement that closed in January 2026. FY 2025 R&D expenses rose 12% to EUR 28.84 million, while G&A expenses were EUR 7.73 million. Chairman and interim CEO Amit Munshi said the GJB2 gene therapy program is on track for a clinical trial application filing in H1 2026, and the company expects to report six-month follow-up data from SENS-501 cohort two in Q1 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sensorion SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260317797443) on March 18, 2026, and is solely responsible for the information contained therein.